Doctors use HLA-B*57:01 genotyping to prevent abacavir hypersensitivity. This genetic test identifies patients at high risk. Abacavir treats HIV effectively. However, it can cause a severe reaction in some people.
The HLA-B*57:01 allele strongly predicts this reaction. Carriers face a much higher chance of developing fever, rash, and organ damage. Therefore, guidelines recommend screening before starting abacavir.
Ethnic variations appear clearly. The allele occurs frequently in people of European descent. Rates reach 5–8% in Caucasian populations. In contrast, it appears rarely in African and East Asian groups. Prevalence drops below 1% in many Asian and sub-Saharan African populations.
These differences affect screening strategies.
In high-prevalence groups, routine genotyping saves lives. It reduces hypersensitivity cases dramatically. In low-prevalence areas, universal screening becomes less practical.
Cost-effectiveness studies support targeted approaches. In populations with high allele frequency, genotyping proves highly cost-effective. It prevents serious reactions and avoids expensive hospital stays. Models show favorable cost per quality-adjusted life year gained.
In low-prevalence settings, the picture changes.
Routine testing costs more than it saves. Selective screening based on ancestry or family history often works better. Some experts advocate no screening in very low-risk groups.
Real-world data confirms benefits. Programs that implemented HLA-B*57:01 testing saw hypersensitivity incidents fall sharply. Patients avoid life-threatening complications. Treatment adherence improves because fear decreases.
Overall, genotyping transforms abacavir use. It personalizes HIV therapy. Ethnic differences guide smart policies. Cost analyses help decide where and how to apply the test. This approach balances safety, equity, and resources in diverse populations.